CCR4 and ovarian cancer: We observed a higher proportion of CCR4+ and CCR7+ Tregs, migratory-related chemokines in the pre-treatment blood of patients with ovarian cancer compared to benign ovarian masses and normal ovaries (Figure 2 and Figure 3); however, these markers were not able to discriminate between those with benign tumors and normal ovaries.